Drug Profile
Research programme: cholera, enterotoxigenic Escherichia coli and typhoid fever vaccine - AVANT Immunotherapeutics
Alternative Names: Peru-15 pCTB/Ty800; Trivalent super-enteric vaccineLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator AVANT Immunotherapeutics
- Developer Celldex Therapeutics Inc
- Class Cholera vaccines; Escherichia coli vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cholera; Escherichia coli infections; Traveller's diarrhoea; Typhoid
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cholera in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Escherichia-coli-infections in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Traveller's-diarrhoea in USA (PO)